lower in the BPH medication cohorts including terazosin than in the no BPH medication cohort.
INTRODUCTION AND OBJECTIVES:
The minimally invasive radiofrequency thermal water vapour thermal therapy (Rezum) and the prostatic lift (Urolift) procedures offer minimally-invasive treatment for lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia. Rezum is a novel treatment modality that has demonstrated safety and efficacy in patients with LUTS. There have been no published head-to-head comparisons of the relative efficacy of the Rezum and Urolift systems. We report an indirect analysis of clinical symptoms and quality of life of two previously published studies of three year outcomes.
METHODS: Clinical outcomes were obtained from published prospective data. International Prostate Symptom Score (IPSS) and IPSS -Quality of Life (QoL), Maximum flow rate (Q-max), post-void residual volume (PVR), Benign Prostate Hyperplasia Impact Index (BPHII) scores along with MSHQ-EjD function and bother domains were outcomes of interest. Outcomes were assessed at 3, 12, 24, and 36 months. The Indirect between-group analysis was followed by a within-group analysis of changes across time points. An adjusted indirect comparison was conducted at 3 years for all outcomes.
RESULTS: All baseline features were similar between the two groups except for Q-max which was higher in the Rezum, and both BPHII and age which were higher in the Urolift group. Compared to the Urolift, the Rez um resulted in an 18.48% and 19.73% greater reduction in IPSS score at 24-months and 36-months (p[0.04). The improvement in the MSHQ-EjD function domain was significantly higher with Urolift at 3,12, 24, and 36 months. Although Q-max improvement was favoured the Rezum group at 3 months (p<0.01) this was not durable. At 36 months the Q-max improvements were not statistically different between the Rezum and Urolift. Regarding MSHQ-EjD bother, the improvements were similar at 12 months and thereafter in both groups.
CONCLUSIONS: This analysis Rezum demonstrated improved relief of LUTS attributed to BPH, with a significantly greater 3 year IPSS improvements compared to Urolift. Despite limitations of the published Urolift study in respect to the exclusion of participants who presented with an obstructive median lobes, considerable relief of LUTS with acceptable morbidity and functional outcomes warrants further of comparison of Rezum against other minimally-invasive surgical therapies for BPH.
Source of Funding: None.
PD19-05 THE OPTIMAL HDL CHOLESTEROL LEVEL FOR PREVENTING BPH REQUIRING TREATMENT USING NATIONAL HEALTH INSURANCE DATABASE
Sangjun Yoo*, Juhyun Park, Sung Yong Cho, Min Chul Cho, Seoul, Korea, Republic of; Jae-Seung Paick, Incheon, Korea, Republic of; Hyeon Jeong, Hwancheol Son, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: We investigated the impacts of high-density lipoprotein (HDL) cholesterol level on the prevalence of benign prostatic hyperplasia (BPH) using a large historical cohort. In addition, we aimed to evaluate the optimal level of HDL cholesterol level in the view of BPH prevention.
METHODS: A total number of 130,454 men who underwent health check-up at 2009 were selected from the National Health Insurance Service health checkup database and divided into 2 groups according to the statin medication usage. A generalized estimating equation (GEE) was performed to assess the impacts of HDL cholesterol level on the prevalence of BPH after adjusting other variables.
RESULTS: 62,783 (51.8%) men used statin medication and 67,559 (48.2%) men did not use statin medication at 2009. Prevalence of BPH at 2009 in statin users was 33.9% and prevalence of BPH in statin non-users was 18.1%. Mean number of annual clinic visits were 23.2 in statin users and 9.9 in statin non-users. In multivariable analysis, increased HDL-cholesterol level was significantly associated with the decreased prevalence of BPH regardless of statin usage after adjusting other variables. In statin nonusers, HDL cholesterol level !60 ng/mL was significantly associated with decreased prevalence of BPH compared to HDL cholesterol level <40 ng/ mL in all age groups. In statin-users, HDL cholesterol level !60 ng/mL was significantly associated with decreased prevalence of BPH compared to HDL cholesterol level <40 ng/mL in all age groups except for 40s. CONCLUSIONS: Serum HDL cholesterol level was associated with the prevalence of BPH. In addition, maintaining HDL cholesterol level !60 ng/mL was associated with the decreased prevalence of BPH compared to those with HDL cholesterol level < 40 ng/mL regardless of statin medication usage.
Source of Funding: None
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